Zobrazeno 1 - 7
of 7
pro vyhledávání: '"PETER N. LAURSEN"'
Publikováno v:
Diabetes. 71
The effect of once-weekly s.c. semaglutide 2.4 mg (sema) on the risk of developing T2D in people with obesity is unknown. Weight management with sema vs. PBO plus diet/exercise was assessed in participants (pts) with overweight/obesity in STEP 1 (68
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c6d3c23b6439ee481c3d3aa7fb23430c
https://doi.org/10.2337/db22-2-lb
https://doi.org/10.2337/db22-2-lb
Autor:
David Lau, John E Deanfield, Melanie Davies, Timothy W Garvey, Ole K Jeppesen, Usman Khalid, Mikhail Kosiborod, Robert F Kushner, Peter N Laursen, Domenica M Rubino, Subodh Verma
Publikováno v:
Canadian Journal of Diabetes. 46:S27-S28
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::58e416d42d8a4c521d417bd173a45bab
https://doi.org/10.1016/j.jcjd.2022.09.079
https://doi.org/10.1016/j.jcjd.2022.09.079
Autor:
Signe O.R. Wallenstein, Leigh Perreault, Anette Varbo, Sriram Machineni, J Wilding, Carel Le Roux, Melanie J. Davies, Juan P. Frias, Ildiko Lingvay, Peter N. Laursen
Publikováno v:
Diabetes. 70
Semaglutide 2.4 mg demonstrated 14.9% body weight (BW) loss in adults with overweight/obesity in STEP 1. We evaluated effects on glucose metabolism in subjects with prediabetes at baseline (BL). Subjects (N=1961) were randomized 2:1 to once-weekly su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::60f6b37e5f0c5eaa86899ebd7cdc2d87
https://doi.org/10.2337/db21-81-or
https://doi.org/10.2337/db21-81-or
Autor:
Subodh Verma, Usman Khalid, Robert F. Kushner, Ole Jeppesen, Domenica Rubino, Peter N. Laursen, Mikhail N. Kosiborod, Melanie J. Davies, W. Timothy Garvey, John E. Deanfield
Publikováno v:
Diabetes. 70
This analysis evaluated the effect of semaglutide 2.4 mg vs. placebo (PBO) or semaglutide 1.0 mg on cardiometabolic risk in STEP 2, a double-blind, placebo-controlled trial in which 1210 adults with overweight/obesity and type 2 diabetes (T2D) were r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f71afc3f6401e269dbb8493fe404052d
https://doi.org/10.2337/db21-80-or
https://doi.org/10.2337/db21-80-or
Autor:
Eskil B. Kreiner, Juris J. Meier, Kamlesh Khunti, Richard E. Pratley, Peter N. Laursen, Silvio E. Inzucchi, Robert Bauer
Publikováno v:
Diabetes. 69
Glucagon-like peptide-1 receptor agonists (GLP-1RA) and SGLT2 inhibitors (SGLTi) are widely used to treat type 2 diabetes (T2D) but trial data on their combined use are limited. We report the first data on oral semaglutide in combination with SGLT2i.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5b11236246cc38f83bf4418cbc389c1
https://doi.org/10.2337/db20-927-p
https://doi.org/10.2337/db20-927-p
Autor:
Juris J. Meier, Richard E. Pratley, Kamlesh Khunti, Ronald Goldenberg, Peter N. Laursen, Eskil B. Kreiner, Robert Bauer
Publikováno v:
Canadian Journal of Diabetes. 44:S24
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a09c3f27c7cf7c8fd9c5832e557c7f95
https://doi.org/10.1016/j.jcjd.2020.08.062
https://doi.org/10.1016/j.jcjd.2020.08.062
Publikováno v:
Blood. 118:384-384
Abstract 384 Fibrinogen: A Procoagulant and an Anticoagulant Introduction: Bleeding occurs secondary to acquired fibrinogen deficiency but the effect of high fibrinogen is more controversial. Correlation between raised fibrinogen levels and venous or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e025f3109e673921bd4e69ca70ca6bef
https://doi.org/10.1182/blood.v118.21.384.384
https://doi.org/10.1182/blood.v118.21.384.384